December 29, 2016 (HealthDay News) Tumors regressed after intracranial infusions of T cells engineered to target tumor-associated antigen Treatment with autologous chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated …
Case Report: Adoptive T-Cell Tx Shows Promise in Glioblastoma Read More
June 20, 2017 (Medical News Today) Immunotherapy drugs continue to only be effective in about 10 to 30 percent of cancer patients with certain tumor types. A clue has been …
Targeting immune cells that help tumors stay hidden could improve immunotherapy Read More
February 16, 2016 (HealthDay News) Patient’s T cells are engineered with chimeric antigen receptors A new T-cell immunotherapy has led to sustained regression in many previously relapsing and treatment-resistant cases …
New Immune Tx Achieves Remission in B-Cell Malignancies Read More
June 6, 2017 (HealthDay News) Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein A new type of immunotherapy appears to provide long-lasting protection against multiple …
ASCO: CAR T-Cell Therapy Promising in Multiple Myeloma Read More
June 12, 2017 (Medical News Today) A nanoparticle has been created by scientists at Johns Hopkins, supporting two unique antibodies that may have the power of “switching off” destructive properties …
“Immunoswitch” particles may be key to more-effective cancer immunotherapy Read More
December 1, 2016 (Blood) “Chimeric antigen receptors (CARs) are fusion proteins that combine antigen-recognition domains and T-cell signaling domains.” T cells harvested from patients’ blood and re-engineered to express CARs …
T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial Read More
June 21, 2016 (Medical News Today) In Phase 2 trials, chimeric antigen receptors (CARs), genetically engineered protein constructs, rewire T-cells in a patient’s own immune system to recognize and destroy …
CAR T-Cell Therapy Can Now Target Solid Tumors: Mouse Study Read More
March 1, 2017 (The Scientist) In the 6-month follow-up for a Phase 2 trial focused on 101 advanced non-Hodgkin lymphoma patients who underwent chimeric antigen receptor T-cell (CAR-T) therapy, 41 …
Kite’s CAR T-Cell Therapy Success Read More
January 5, 2017 (ScienceDaily.com) Lymphoma, the most common blood cancer, is the result of the uncontrollable multiplication of lymphocytes (immune cells). B-cell lymphomas account for 85% of patients who have …
Immune cell therapy shows promising results for lymphoma patients Read More
February 6, 2017 (The Journal of Clinical Investigation) Part of the reason why treatment of solid tumors using CAR T-cells has been troublesome is because of adenosine production. Production of …
Targeting Adenosine 2A Receptors Enhances CAR T-Cell Efficacy Read More